The latest update is out from BioMarin Pharmaceutical ( (BMRN) ).

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) ("BioMarin") announced today that it closed its previously announced offering of $850 million of 5.500% senior unsecured notes due 2034 (the "Notes"). The ...

Shares of BioMarin Pharmaceutical (NASDAQ:BMRN) and Ascendis Pharma (NASDAQ:ASND) fell roughly 6% after rival BridgeBio ...

BioMarin Pharmaceutical (NASDAQ:BMRN) and Ascendis Pharma (NASDAQ:ASND) stocks dropped approximately 6% following the release ...

BridgeBio Pharma’s experimental drug for the most common cause of dwarfism accelerated children’s growth in a pivotal clinical trial.

The rare disease drugmaker is facing potential competitors for achondroplasia drug Voxzogo. Is a big M&A deal with two ...

By Michael Erman SAN FRANCISCO, Feb 11 (Reuters) - Some pharmaceutical companies not targeted by President Donald Trump for ...

BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the most promising future stocks to buy now. Piper Sandler revised the ...

Barclays initiated coverage of BioMarin on January 28, assigning it an “Overweight” rating and a target price of $80. This ...

In what is shaping up to be a back-loaded month, the FDA is set to release a slew of regulatory decisions in February, ...

BioMarin Pharmaceutical's (BMRN 0.82%) website doesn't show any scheduled events on its calendar over the next month. However ...